BeiGene, Ltd., soon to be rebranded as BeOne Medicines Ltd., has disclosed a global licensing deal with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CSPC) for SYH2039. This innovative methionine adenosyltransferase 2A (MAT2A) inhibitor is in exploration for potential uses in treating solid tumors.
SYH2039 is specifically aimed at combating solid tumors characterized by MTAP deletion mutations, commonly found in about 15% of cancer types, including glioblastoma, pancreatic cancer, and non-small cell lung cancer.
“In our efforts to maintain one of the industry’s most dynamic solid tumor pipelines, we are continuously evaluating opportunities aligned with our strategic goals to meet significant patient needs. This MAT2A inhibitor adds substantial value to our solid tumor research, and we are enthusiastic about exploring its potential, notably alongside our PRMT5 inhibitor, BGB-58067, developed in-house. These two assets combined may significantly advance treatments across various solid tumors,” stated Lai Wang, Ph.D., who leads global R&D at BeiGene.
The promising BGB-58067 is expected to commence clinical trials by year-end, designed to mitigate the hematological toxicity associated with earlier PRMT5 inhibitors, and shows potential to be best-in-class due to its high efficacy, selectivity, and ability to penetrate the brain.
Per the agreement, BeiGene receives exclusive rights to globally develop, produce, and commercialize SYH2039, while CSPC will be compensated with upfront and milestone-based payments totaling $150 million, in addition to tiered royalties.
BeiGene’s strategy towards leading in solid tumor treatment includes the PD-1 inhibitor Tevimbra (tislelizumab) and advancing potentially superior assets for lung, breast, and gastrointestinal cancers. This includes distinct antibody-drug conjugates, multi-specific antibodies, protein degraders, and small molecule inhibitors. With plans to rebrand as BeOne, the company stands committed to innovating therapies aiming to cure cancer and collaborate globally to make treatments available to diverse patient populations.
BeiGene’s new identity as BeOne Medicines will reinforce its dedication to providing innovative, affordable cancer treatments worldwide.